Quote | Vor Biopharma Inc. (NASDAQ:VOR)
Last: | $1.68 |
---|---|
Change Percent: | -1.18% |
Open: | $1.71 |
Close: | $1.70 |
High: | $1.719 |
Low: | $1.65 |
Volume: | 111,163 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
News | Vor Biopharma Inc. (NASDAQ:VOR)
2024-03-28 16:52:13 ET Gainers: Semtech Corporation ( SMTC ) +10% . Zentalis Pharmaceuticals ( ZNTL ) +9% . Sagimet Biosciences ( SGMT ) +5% . Photronics ( PLAB ) +5% . James River Group Holdings ( JRVR ) +4% . Losers...
2024-03-22 16:59:35 ET Gainers: Masimo ( MASI ) +12% . Pliant Therapeutics ( PLRX ) +5% . Vor Biopharma ( VOR ) +5% . Vor Biopharma ( CNDT ) +4% . Xometry ( XMTR ) +4% . Losers: Airship AI Holdings ( AISP ) -7% . ...
Message Board Posts | Vor Biopharma Inc. (NASDAQ:VOR)
Subject | By | Source | When |
---|---|---|---|
znewcar1: $VOR 41% v4,06M C6.10 f38,666MH6.70 ML3.87 | znewcar1 | investorshangout | 12/07/2022 10:37:22 PM |
News, Short Squeeze, Breakout and More Instantly...
Vor Biopharma Inc. Company Name:
VOR Stock Symbol:
NASDAQ Market:
Trem-cel and VCAR33 ALLO clinical trial data expected in the second half of 2024 VCAR33 ALLO granted Fast Track and Orphan Drug Designation by U.S. Food & Drug Administration Cash runway extends into second half of 2025 CAMBRIDGE, Mass., March...
CAMBRIDGE, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the Oppenheimer 34 th Annual Healthcare Life Sciences Conferen...
First patient dosed in company’s second clinical program with initial data expected in second half of 2024 Cash runway extended into second half of 2025 with clinical trials on track CAMBRIDGE, Mass., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-sta...